Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003855 · ClinicalTrials.gov registry record · Phase 3
Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 3
- Development phase
- 605
- Enrollment target
- 20
- Study locations
NCT00003855 is a Phase 3 study of Breast Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 605 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT00003855, a Phase 3 study of Breast Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 605 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Surgery to remove lymph nodes in the armpit may remove cancer cells that have spread from tumors in the breast. PURPOSE: Randomized phase III trial to determine the effectiveness of removing lymph nodes in the armpit in treating women who have stage I or stage IIA breast cancer.
Conditions Studied
Interventions
- RADIATION whole breast irradiation
- PROCEDURE axillary lymph node dissection
Study Locations (20)
California
- Mercy San Juan Hospital - Carmichael
- Arrowhead Regional Medical Center - Colton
- Mount Diablo Regional Cancer Center - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- Loma Linda University Cancer Institute at Loma Linda University Medical Center - Loma Linda
- Summit Medical Center - Oakland
- St. Joseph Hospital Regional Cancer Center - Orange - Orange
- Palo Alto Medical Foundation - Palo Alto
- Huntington Cancer Center at Huntington Hospital - Pasadena
- Shasta Regional Medical Center - Redding
- University of California Davis Cancer Center - Sacramento
- Sharp Memorial Hospital - San Diego
Arkansas
- Washington Regional Medical Center - Fayetteville
- St. Vincent Doctors Doctors Hospital - Little Rock
- Baptist Health Medical Center - Little Rock
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Alabama
- University of Alabama at Birmingham Comprehensive Cancer Center - Birmingham
- Providence Cancer Center - Mobile
- Mobile Infirmary Medical Center - Mobile
Arizona
- CCOP - Mayo Clinic Scottsdale Oncology Program - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 605 participants |
| Start Date | 1999-04 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003855
The ClinicalTrials.gov registry entry for NCT00003855 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 605 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (78% lower). The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which whole breast irradiation is the first listed.
NCT00003855 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arkansas, Alabama.
Frequently Asked Questions
What is clinical trial NCT00003855 about?
NCT00003855 is a clinical study titled "Lymph Node Removal in Treating Women Who Have Stage I or Stage IIA Breast Cancer". RATIONALE: Surgery to remove lymph nodes in the armpit may remove cancer cells that have spread from tumors in the breast. PURPOSE: Randomized phase III trial to determine the effectiveness of removing lymph nodes in the armpit in treating women who have stage I or stage IIA breast cancer.
What is the current status of trial NCT00003855?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 605 participants. The study started on 1999-04. Estimated completion is 2011-02.
What conditions does trial NCT00003855 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00003855?
The interventions under investigation include: whole breast irradiation (RADIATION), axillary lymph node dissection (PROCEDURE).
Who is sponsoring clinical trial NCT00003855?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003855 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.